Article citationsMore>>

Pachman, L.M., Abbott, K., Sinacore, J.M., Amoruso, L., Dyer, A., Lipton, R., Ilowite, N., Hom, C., Cawkwell, G., White, A., Rivas-Chacon, R., Kimura, Y., Ray, L. and Ramsey-Goldman, R. (2006) Duration of Illness Is an Important Variable for Untreated Children with Juvenile Dermatomyositis. The Journal of Pediatrics, 148, 247-253.
https://doi.org/10.1016/j.jpeds.2005.10.032

has been cited by the following article:

• TITLE: Effectiveness of Rituximab Therapy on Severe Calcinosis in 4 Children with Juvenile Dermatomyositis

  AUTHORS: Mohammad Alhemairi, Mohammed Muzaffer

  KEYWORDS: Calcinosis, Rituximab, Juvenile Dermatomyositis

  JOURNAL NAME: Open Journal of Rheumatology and Autoimmune Diseases, Vol.7 No.1, January 6, 2017

  ABSTRACT: Background: Calcinosis is an important sequela of JDM which may cause significant morbidity and mortality. There is no standard curative treatment for calcinosis but different agents were used with variable efficacy. We report the favorable outcome of rituximab on severe calcinosis in 4 JDM patients and present their clinical data. Patients and Methods: A retrospective chart review of 4 children with JDM and severe calcinosis who received rituximab for relapsing or polycyclic JDM course. Diagnosis and follow up of calcinosis was clinically and by X-ray. Review data included: age of patients at onset of JDM symptoms and diagnosis, clinical and laboratory criteria at diagnosis, disease course and duration of follow up. Data about calcinosis onset, sites, severity and its progression were also included. Further data about rituximab therapy included: dosage, side effects, other treatment used before, during or after this drug and outcome and duration of follow up of calcinosis after therapy. Results: 4 patients (2 male, 2 female), interval between onset of symptoms and diagnosis was 6 - 12 months, course of JDM was polycyclic or relapsing, duration of follow up was 5 - 7 years. Calcinosis was severe causing ulceration, recurrent skin infections and joint limitation. It was not improving despite treatment with different DMARDs and/or bisphosphonates, colchicine and warfarin. Reason to start rituximab was inadequate disease control with conventional DMARDs. All patients received steroids and more than one DMARD before starting rituximab and were continued thereafter, follow up after rituximab was 3 to 5 years. All patients had improvement in disease activity and frequency of admission especially due to complications of calcinosis. One patient had complete clearance of calcinosis for the last 5 years. Others had significant improvement in calcinosis with no new lesions, decreased sites and density and decreased calcinosis related contractures. There were no serious side effects to rituximab. Conclusion: Our study showed the favorable effect of rituximab in treatment of calcinosis in 4 patients with JDM-associated severe calcinosis when it was used with other conventional DMARDs.